Véronique Baudouin

Véronique Baudouin

Auto-generated profile, based on publicly available information

Véronique Baudouin

Pediatric Nephrology, Dialysis and Transplantation Department, Robert Debré University Hospital, APHP, Paris Cité University, Paris, France

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
CDClaire Dossier
Claire Dossier
SBStéphanie Bonneric
Stéphanie Bonneric
VBVéronique Baudouin
Véronique Baudouin
TKThérésa Kwon
Thérésa Kwon
BPBenjamin Prim
Benjamin Prim
JHJulien Hogan
Julien Hogan
Background: B-cell depletion with rituximab induces sustained remission in children with steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients relapse after B-cell recovery, and some patients do not achieve B-cell depletion. Obinutuzumab is a second-generation anti-CD20 antibody designed to overcome such situations in B-cell malignancies and was recently reported to be safe and effective in other autoimmune diseases affecting the kidneys. Methods: We retrospectively report 41 children with steroid-dependent or frequently relapsing nephrotic syndrome treated with a single low-dose infusion of obinutuzumab at Robert-Debre Hospital between April 2018 and December 2020. Participants were treated because of rituximab resistance or relapse after rituximab and received a single infusion of 300 mg/1.73 m2 obinutuzumab with cessation of oral immunosuppressors within 2 months. Results: B-cell depletion was achieved in all participants and lasted a median of 8.3 months (interquartile range, 6.4–11.1), a duration exceeding that for last rituximab treatment. At 12 and 24 months, 92% (38/41) and 68% (28/41) of patients, respectively, were in sustained remission. Mild infusion reactions occurred in five participants (12%) and neutropenia in nine (21%). No significant decrease in IgG level was reported during treatment, and whereas IgM levels decreased in 34 patients (83%), they were normal at last follow-up in 32 (78%). Conclusions: These results identified low-dose obinituzumab as a promising treatment option in children with steroid-dependent or frequently relapsing nephrotic syndrome, including those resistant to rituximab. The tolerance profile of obinutuzumab was similar to that of rituximab, but hemogram and immunoglobulin levels should be monitored.

1 May 2009 in Clinical Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
WZWei Zhao
Wei Zhao
VBVéronique Baudouin
Véronique Baudouin
DZDaolun Zhang
Daolun Zhang
GDGeorges Deschênes
Georges Deschênes
CGChantal Le Guellec
Chantal Le Guellec
Evelyne Jacqz-AigrainEvelyne Jacqz-Aigrain
Evelyne Jacqz-Aigrain

24 August 2023 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
MMMarie Sophie Meuleman
Marie Sophie Meuleman
PVPaula Vieira-Martins
Paula Vieira-Martins
CSCarine El Sissy
Carine El Sissy
VAVincent AUDARD
Vincent AUDARD
VBVéronique Baudouin
Véronique Baudouin
SCSophie Chauvet
Sophie Chauvet
Background: C3 glomerulopathy and idiopathic immunoglobulin-mediated membranoproliferative GN (Ig-MPGN) are rare complement-mediated kidney diseases. Inherited forms of C3 glomerulopathy/Ig-MPGN are rarely described. Methods: Three hundred ninety-eight patients with C3 glomerulopathy (n=296) or Ig-MPGN (n=102) from a national registry were screened for three complement genes: factor H (CFH), factor I (CFI), and C3. Patients with rare variant (minor allele frequency <0.1%) were included. Epidemiologic, clinical, and immunologic data at diagnosis and kidney outcomes of patients were retrospectively collected. Results: Fifty-three different rare variants, including 30 (57%), 13 (24%), and ten (19%) in CFH, CFI, and C3 variants, were identified in 66/398 (17%) patients. Thirty-eight (72%) variants were classified as pathogenic, including 20/30 (66%) and 11/13 (84%) variants in CFH and CFI, respectively, impairing synthesis of factor H or factor I regulators. Fifteen of 53 (27%) variants were of unknown significance. At diagnosis, 69% of patients were adult (median age of 31 years). With the exception of biologic stigma of thrombotic microangiopathy, which was more frequent in patients with CFI variants (5/14 [36%] versus 1/37 [3%] and 0% in the CFH group and C3 group, respectively, P < 0.001), the clinical and histologic features were similar among the three variants groups. The kidney outcome was poor regardless of the age at onset and treatment received. Sixty-five percent (43/66) of patients with rare variant reach kidney failure after a median delay of 41 (19–104) months, compared with 28% (55/195) after a median delay of 34 (12–143) months in the nonvariant group. Among 36 patients who received a kidney transplant, 2-year recurrence was frequent, occurring in 39% (12/31), without difference between variant groups, and led to graft failure in three cases. Conclusions: In our cohort, 17% of C3 glomerulopathy/Ig-MPGN cases were associated with rare variants in the CFH, CFI, or C3 genes. In most cases, a quantitative deficiency in factor H or factor I was identified. The presence of a rare variant was associated with poor kidney survival. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mp3/www.asn-online.org/media/podcast/CJASN/2023_11_08_CJN0000000000000252.mp3

26 March 2013 in Pediatric Pulmonology
Verified
Journal Article
Closed access
PDF file
SASalma Ben Ameur
Salma Ben Ameur
PNPatrick Niaudet
Patrick Niaudet
VBVéronique Baudouin
Véronique Baudouin
MBMuriel Le. Bourgeois
Muriel Le. Bourgeois
VHVéronique Houdouin
Véronique Houdouin
AHAlice Hadchouel
Alice Hadchouel

8 January 2022 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
ACAlexandra Cambier
Alexandra Cambier
CDClaire Dossier
Claire Dossier
JHJulien Hogan
Julien Hogan
VBVéronique Baudouin
Véronique Baudouin
AMAnne Maisin
Anne Maisin
RMRenato Monteiro
Renato Monteiro

19 September 2024 in Pediatric Nephrology
Verified
Journal Article
Closed access
PDF file
CDCharlotte Duneton
Charlotte Duneton
TKTheresa Kwon
Theresa Kwon
CDClaire Dossier
Claire Dossier
VBVeronique Baudouin
Veronique Baudouin
MFMarc Fila
Marc Fila
JHJulien Hogan
Julien Hogan